Benjamin M. Hiller

Benjamin M. Hiller

Auto-generated profile, based on publicly available information

Benjamin M. Hiller

Department of Neurological Sciences Rush University, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Stem Cell Reports
Verified
Journal Article
Open access
DWDustin R. Wakeman
Dustin R. Wakeman
BHBenjamin M. Hiller
Benjamin M. Hiller
DMDavid J. Marmion
David J. Marmion
CMChristopher W. McMahon
Christopher W. McMahon
GCGrant Corbett
Grant Corbett
JKJeffrey H. Kordower
Jeffrey H. Kordower
A major challenge for clinical application of pluripotent stem cell therapy for Parkinson's disease (PD) is large-scale manufacturing and cryopreservation of neurons that can be efficiently prepared with minimal manipulation. To address this obstacle, midbrain dopamine neurons were derived from human induced pluripotent stem cells (iPSC-mDA) and cryopreserved in large production lots for biochemical and transplantation studies. Cryopreserved, post-mitotic iPSC-mDA neurons retained high viability with gene, protein, and electrophysiological signatures consistent with midbrain floor-plate lineage. To test therapeutic efficacy, cryopreserved iPSC-mDA neurons were transplanted without subculturing into the 6-OHDA-lesioned rat and MPTP-lesioned non-human-primate models of PD. Grafted neurons retained midbrain lineage with extensive fiber innervation in both rodents and monkeys. Behavioral assessment in 6-OHDA-lesioned rats demonstrated significant reversal in functional deficits up to 6 months post transplantation with reinnervation of the host striatum and no aberrant growth, supporting the translational development of pluripotent cell-based therapies in PD.

30 September 2020 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
BHBenjamin M. Hiller
Benjamin M. Hiller
DMDavid J. Marmion
David J. Marmion
RGRachel M. Gross
Rachel M. Gross
CTCayla A. Thompson
Cayla A. Thompson
CCCarrie A. Chavez
Carrie A. Chavez
JKJeffrey H. Kordower
Jeffrey H. Kordower
Nongenetic methodologies to reduce undesirable proliferation would be valuable when generating dopamine neurons from stem cells for transplantation in Parkinson's disease (PD). To this end, we modified an established method for controlled differentiation of human induced pluripotent stem cells (iPSCs) into midbrain dopamine neurons using two distinct methods: omission of FGF8 or the in-process use of the DNA cross-linker mitomycin-C (MMC). We transplanted the cells to athymic rats with unilateral 6-hydroxydopamine lesions and monitored long-term survival and function of the grafts. Transplants of cells manufactured using MMC had low proliferation while still permitting robust survival and function comparable to that seen with transplanted dopamine neurons derived using genetic drug selection. Conversely, cells manufactured without FGF8 survived transplantation but exhibited poor in vivo function. Our results suggest that MMC can be used to reduce the number of proliferative cells in stem cell-derived postmitotic neuron preparations for use in PD cell therapy.